Psoriatic erythroderma. Therapeutic review and update
DOI:
https://doi.org/10.47196/da.v29i1.2306Keywords:
erythroderma, psoriasis, treatment, biologicalsAbstract
Erythroderma is a condition characterized by erythema and scaling involving at least 90% of the body surface. Its etiology can be variable. Most of its clinical features and laboratory abnormalities are nonspecific, making diagnosis challenging. Psoriatic erythroderma (PE) is a rare and infrequent form of psoriasis. The evidence in the literature examining treatment options for psoriatic erythroderma is of low quality. This lack of literature is likely a result of the low incidence of this form of psoriasis and the acuity with which patients can present, often requiring immediate pharmacological intervention for rapid disease control. This review work aims to provide updated information for the treatment of psoriatic erythroderma.
References
I. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26:314-320.
II. Ladizinski B, Lee KC, Wilmer E, Alavi A, et ál. A review of the clinical variants and the management of psoriasis. Adv Skin Wound Care. 2013;26:271-284; quiz 285-286.
III. Lebwohl M. Psoriasis. Lancet. 2003;361:1197-1204.
IV. Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227-255.
V. di Prinzio A, Torre AC, Cura MJ, Puga C, Bastard DP, Mazzuoccolo LD. Adverse Drug Reactions Are the Main Causes of Erythroderma in an Argentinian Teaching Hospital: A Retrospective Study of 70 Patients. Actas Dermosifiliogr. 2022;113:765-772.
VI. Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnóstico y clasificación de la psoriasis. Autoimmun Rev. 2014;13:490-495.
VII. Zhang P, Chen HX, Duan YQ,Wang WZ, et ál. Analysis of Th1/Th2 response pattern for erythrodermic psoriasis. J Huazhong Univ Sci Technolog Med Sci. 2014;34:596-601.
VIII. Li LF, Sujan SA, Yang H, Wang W-H. Serum immunoglobulins in psoriatic erythroderma. Clin Exp Dermatol. 2005;30:125-127.
IX. Deeva I, Mariani S, De Luca C, Pacifico V, et ál. Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease. Cytokine. 2010;49:163-170.
X. Groves RW, Kapahi P, Barker JN, Haskard DO, et ál. Detection of circulating adhesion molecules in erythrodermic skin disease. J Am Acad Dermatol. 1995;32:32-36.
XI. Moy AP, Murali M, Kroshinsky D, Duncan LM, Nazarian RM. et ál. Immunologic Overlap of Helper T-Cell Subtypes 17 and 22 in Erythrodermic Psoriasis and Atopic Dermatitis. JAMA Dermatol. 2015;151:753-760.
XII. Viguier M, Pages C, Aubin F, Delaporte E, et ál. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Br J Dermatol. 2012;167:417-423.
XIII. Van Dooren-Greebe RJ, Kuijpers AL, Mulder J, De Boo T. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol. 1994;130:204-210.
XIV. Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years’ experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol. 2000;14:382-388.
XV. Kumar B, Dhar S, Handa S, Kaur I. Methotrexate in childhood psoriasis. Pediatr Dermatol. 1994;11:271-273.
XVI. Khaled A, Ben Hamida M, Zeglaoui F, Kharfi M, et ál. Traitement du psoriasis par méthotrexate à l’ère des biothérapies : étude chez 21 patients tunisiens. Thérapie. 2012;67:49-52.
XVII. Lim KK, Su WP, Schroeter AL, Sabers CJ, et ál. Cyclosporine in the treatment of dermatologic disease: an update. Mayo Clin Proc. 1996;71:1182-1191.
XVIII. Studio Italiano Multicentrico nella Psoriasi (SIMPSO). Management of erythrodermic psoriasis with low-dose cyclosporine. Dermatology. 1993;187:30-37.
XIX. Bruzzese V, Pepe J. Efficacy of cyclosporine in the treatment of a case of infliximab-induced erythrodermic psoriasis. Int J Immunopathol Pharmacol. 2009;22:235-238.
XX. Ahdout J, Mandel H, Chiu M. Erythroderma in a patient taking acitretin for plaque psoriasis. J Drugs Dermatol. 2008;7:391-394.
XXI. Sprecher E, Bergman R, Friedman-Birnbaum R. Cyclosporine treatment of psoriatic erythroderma complicated by bacterial sepsis. J Eur Acad Dermatol Venereol. 1999;12:197-198.
XXII. Borghi A, Corazza M, Mantovani L, Bertoldi AM, et ál. Prolonged cyclosporine treatment of severe or recalcitrant psoriasis: descriptive study in a series of 20 patients. Int J Dermatol. 2012;51:1512-1516.
XXIII. Prossick TA, Belsito DV. Alefacept in the treatment of recalcitrant palmoplantar and erythrodermic psoriasis. Cutis. 2006;78:178-180.
XXIV. Brechtel B, Wellenreuther U, Toppe E, Czarnetski BM. Combination of etretinate with cyclosporine in the treatment of severe recalcitrant psoriasis. J Am Acad Dermatol. 1994;30:1023-1024.
XXV. Kokelj F, Plozzer C, Torsello P, Trevisan G. Efficacy of cyclosporine plus etretinate in the treatment of erythrodermic psoriasis (three case reports). J Eur Acad Dermatol Venereol. 1998;11:177-179.
XXVI. Korstanje MJ, Bessems PJ. Combination therapy ciclosporin-etretinate effective in erythrodermic psoriasis. Dermatologica. 1989;179:94.
XXVII. Franchi C, Cainelli G, Frigerio E, Garutti C, et ál. Association of cyclosporine and 311 nM UVB in the treatment of moderate to severe forms of psoriasis: a new strategic approach. Int J Immunopathol Pharmacol. 2004;17:401-406.
XXVIII. Charbit L, Mahé E, Phan A, Chiaverini C, et ál. Systemic treatments in childhood psoriasis: a French multicentre study on 154 children. Br J Dermatol. 2016;174:1118-1121.
XXIX. Kuijpers ALA, van Dooren-greebe RJ, van de Kerkhof PCM. Failure of Combination Therapy with Acitretin and Cyclosporin A in 3 Patients with Erythrodermic Psoriasis. Dermatology. 1997;194:88-90.
XXX. Rosenbach M, Hsu S, Korman NJ, Lebwohl, MG, et ál. Treatment of erythrodermic psoriasis: From the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;2:655-662.
XXXI. Kim BS, Shin KS, Youn JI, Lee YS. Treatment of erythrodermic psoriasis with etretinate. Ann Dermatol. 1991;3:107-111.
XXXII. Rosińska D, Wolska H, Jablonska S, Konca I. Etretinate in severe psoriasis of children. Pediatr Dermatol. 1988;5:266.
XXXIII. Tuyp E, MacKie RM. Combination therapy for psoriasis with methotrexate and etretinate. J Am Acad Dermatol. 1986;14:70-73.
XXXIV. Roeder C. Psoriatic erythroderma and bullous pemphigoid treated successfully with acitretin and azathioprine. Eur J Dermatol. 1999;9:537-539.
XXXV. Takahashi MDF, Castro LG, Romiti R. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. Br J Dermatol. 2007;157:828-831.
XXXVI. Ahdout J, Mandel H, Chiu M. Erythroderma in a patient taking acitretin for plaque psoriasis. J Drugs Dermatol. 2008;7:391.
XXXVII. Ling MR. Acitretin: optimal dosing strategies. J Am Acad Dermatol. 1999;41:S13–17.
XXXVIII. Geilen CC, Tebbe B, Garcia Bartels C, Krengel S, et ál. Successful treatment of erythrodermic psoriasis with mycophenolate mofetil. Br J Dermatol. 1998;138:1101-1102.
XXXIX. Esposito M, Mazzotta A, de Felice C, Papoutsaki M, Chimenti S. Treatment of erythrodermic psoriasis with etanercept. . Br J Dermatol. 2006;155:156-159.
XL. Pique-Duran E, Perez-Cejudo JA. Psoriatic erythroderma treated with etanercept. Actas Dermosifiliogr. 2007;98:508-510.
XLI. Romero-Maté A, García-Donoso C, Martinez-Morán C, Hernández-Núñez, et ál. Long-term management of erythrodermic psoriasis with anti-TNF agents. Dermatol Online J. 2010;16:15.
XLII. Viguier M, Pagès C, Aubin F, Delaporte E, et ál. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Br J Dermatol. 2012;167:417-423.
XLIII. Sahel H, Bouadjar B. Treatment of Erythrodermic Psoriasis with Infliximab and Etanercept in Two Cases. J Clinic Exper Cosme Dermatol. 2017;1:002.
XLIV. Fraga NA, Paim Mde F, Follador I, Ramos AN, et ál. Refractory erythrodermic psoriasis in a child with an excellent outcome by using etanercept. An Bras Dermatol. 2011;86:S144-S147.
XLV. Poulalhon N, Begon E, Lebbé C, Lioté F, et ál. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol. 2007;156:329-336.
XLVI. Lisby S, Gniadecki R. Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis. Acta Derm Venereol. 2004;84:247-248.
XLVII. Heikkila H, Ranki A, Cajanus S, Karvonen SL. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis. Arch Dermatol. 2005;141:1607-1610.
XLVIII. Mahé E, Descamps V, Grossin M, Fraitag S, et ál. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol. 2003;149:170-173.
XLIX. Rongioletti F, Borenstein M, Kirsner R, Kerdel F. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab. J Dermatol Treat. 2003;14:222-225.
L. Torii H, Nakagawa H. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J Dermatol. 2011;38:321-334.
LI. Lewis TG, Tuchinda C, Lim HW, Wong HK. Life-threatening pustular and erythrodermic psoriasis responding to infliximab. J Drugs Dermatol. 2006;5:546-548.
LII. O’Quinn RP, Miller JL. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases. Arch Dermatol. 2002;138:644-648.
LIII. Fiehn C, Andrassy K. Case number 29: hitting three with one strike: rapid improvement of psoriatic arthritis, psoriatic erythroderma, and secondary renal amyloidosis by treatment with infliximab (Remicade). Ann Rheum Dis. 2004;63:232.
LIV. Yip L, Harrison S, Foley P. From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis. Australas J Dermatol. 2008;49:152-155.
LV. Tridico LA, Antonio JR, Mathias CE, Pozetti EMO. Effectiveness and safety of infliximab for 11 years in a patient with erythrodermic psoriasis and psoriatic arthritis. An Bras Dermatol. 2017;92:743-745.
LVI. Valdés A, Mdel P, Schroeder HF, Roizen GV, et ál. Efficacy of infliximab in patients with moderate and severe psoriasis treated with infliximab (Remicade). Rev Med Chil. 2006;134:326-331.
LVII. Kurokawa R, Hagiwara A, Niijima Y, Kojima K. Computed tomography imaging findings in erythrodermic psoriasis treated with infliximab: a case report. Radiol Case Rep. 2018;13:460-463.
LVIII. Belinchon I, Lucas A, Ballester I, Betlloch I, et ál. Successful treatment of life threatening erythrodermic psoriasis with infliximab. J Am Acad Dermatol. 2009;60:AB171.
LIX. Suárez Pedreira I, Santos Juanes J, Caminal Montero L, Trapiella L. Infliximab: an alternative in refractory erythrodermic psoriasis. Piel. 2006;21:317-318.
LX. Carrasquillo OY, Pabón-Cartagena G, Falto-Aizpurua LA, Santiago-Vazquez, et ál. Treatment of erythrodermic psoriasis with biologics: a systematic review. J Am Acad Dermatol. 2020;83:151-158.
LXI. Suzuki E, Mellins ED, Gershwin ME, Nestle FO, Adamopoulos IE. The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev. 2014;13:496-502.
LXII. Girolomoni G, Strohal R, Puig L, Bachelez H, et ál. The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017;31:1616-1626.
LXIII. Pescitelli L, Dini V, Gisondi P, Loconsole F, et ál. Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis. J Dermatol Sci. 2015;78:149-151.
LXIV. Wang TS, Tsai TF. Clinical experience of ustekinumab in the treatment of erythrodermic psoriasis: a case series. J Dermatol. 2011;38:1096-1099.
LXV. Stinco G, Piccirillo A, Errichetti E, Bergamo S, et ál. Treatment of recalcitrant erythrodermic psoriasis with ustekinumab. Eur J Dermatol. 2014;24:387-390.
LXVI. Saraceno R, Talamonti M, Galluzzo M, Chiricozzi A, et ál. Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases. Case Rep Dermatol. 2013;5:254-259.
LXVII. Yiu Z, Becher G, Kirby B, Laws P, et ál. Drug Survival Associated with Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis. JAMA Dermatol. 2022;158:1131-1141.
LXVIII. Buggiani G, D’Erme AM, Krysenka A, Pescitelli L, et ál. Efficacy of ustekinumab in sub-erythrodermic psoriasis: when TNF-blockers fail. Dermatol Ther. 2012;25:283-285.
LXIX. Castiñeiras I, Fernández-Diaz L, Juárez Y, Lueiro M. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies. J Dermatol. 2012;39:730-731.
LXX. Concha-Garzón MJ, Godoy-Trapero A, Daudén E. Short- and long-term treatment of erythrodermic psoriasis with ustekinumab: a national and multicenter case series. J Am Acad Dermatol. 2014;70:AB189.
LXXI. Sano S, Kubo H, Morishima H, Goto R, et ál. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45:529-539.
LXXII. Chiang CY, Tsai TF. Treatment Response of Patients with Erythrodermic Psoriasis after Switching to Guselkumab. Dermatol Ther (Heidelb). 2021;11:301-306.
LXXIII. Brembilla NC, Senra L, Boehncke WH. The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond. Front Immunol. 2018;9:1682.
LXXIV. Krueger JG, Fretzin S, Suarez-Farinas M, Haslett PA, et ál. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130:145–54 e9.
LXXV. Mateu-Puchades A, Santos-Alarcón S, Martorell-Calatayud A, Pujol-Marco C, et ál. Erythrodermic psoriasis and secukinumab: our clinical experience. Dermatol Ther. 2018;31:e12607.
LXXVI. Galluzzo M, D’Adamio S, Campione E, Mazzilli S, et ál. A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab. J Dermatolog Treat. 2018;29:1-11.
LXXVII. Rongioletti F, Mugheddu C, Murgia S. Repigmentation and new growth of hairs after anti–interleukin-17 therapy with secukinumab for psoriasis. JAAD Case Rep. 2018;4:486-488.
LXXVIII. Dogra S, Bishnoi A, Narang T, Handa S. Long-term remission induced by secukinumab in a 13-year-old boy having recalcitrant chronic erythrodermic psoriasis. Dermatol Ther. 2018;31e12611.
LXXIX. Tichy M. Arthropathic psoriasis complicated by a paradoxical reaction in the form of erythrodermic psoriasis following adalimumab and by an allergic reaction following infliximab which was successfully managed with secukinumab. Postepy Dermatol Alergol. 2019;36:495-497.
LXXX. Damiani G, Pacifico A, Russo F, Pigatto, et ál. Use of secukinumab in a cohort of erythrodermic psoriatic patients: a pilot study. J Clin Med. 2019;8:770.
LXXXI. Shibata T, Muto J, Takama H, Yanagishita T, et ál. Case of psoriatic erythroderma induced by the discontinuation of the chronic use of topical steroid after dialysis initiation and successfully treated with secukinumab. J Dermatol. 2019;46:e119-20.
LXXXII. Pizzatti L, Mugheddu C, Sanna S, Atzori L, et ál. Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab. Dermatol Ther. 2020;33:e13348.
LXXXIII. Liu LC, Jin XH, Sun C, Xia JX. Two cases of refractory erythrodermic psoriasis effectively treated with secukinumab and a review of the literature. Dermatol Ther. 2021;34:e14825.
LXXXIV. Saeki H, Nakagawa H, Nakajo K, Ishii T et ál. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44:355-362.
LXXXV. Okubo Y, Mabuchi T, Iwatsuki K, Elmaraghy H, et ál. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J). J Eur Acad Dermatol Venereol. 2019;33:325-332.
LXXXVI. Papp K, Cather JC, Rosoph L, Sofen H, et ál. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380(9843):738–46114.
LXXXVII. Krishnamoorthy G, Kotecha A, Pimentel J. Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy. BMJ Case Rep. 2019;12:e226959.
LXXXVIII. Papadavid E, Kokkalis G, Polyderas G, Theodoropoulos K, et ál. Rapid clearance of erythrodermic psoriasis with apremilast. J Dermatol Case Rep. 2017;11:29-31.
LXXXIX. Gregoire ARF, DeRuyter BK, Stratman EJ. Psoriasis Flares Following Systemic Glucocorticoid Exposure in Patients With a History of Psoriasis. JAMA Dermatol. 2021;157:198-201.
XC. Mrowietz U, Domm S. Systemic steroids in the treatment of psoriasis: what is fact, what is fiction? J Eur Acad Dermatol Venereol. 2013;27:1022-1025.
XCI. Cretu S, Salavastru CM, Tiplica GS. Treatment of psoriatic erythroderma using systemic corticosteroids: a timeless option? Dermatol Ther. 2020;33:e14222.
XCII. Reynolds KA, Pithadia DJ, Lee EB, Liao W, et ál. A systematic review of treatment strategies for erythrodermic psoriasis. J Dermatolog Treat. 2021;32:49-55.
XCIII. Shao S, Wang G, Maverakis E, Gudjonsson JE. Targeted Treatment for Erythrodermic Psoriasis: rationale and recent advances. Drugs. 2020;80:525-534.
XCIV. Hsu SH, Tsai TF. Evolution of the inclusion/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis. Expert Rev Clin Pharmacol. 2020;13:211-232.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 on behalf of the authors. Reproduction rights: Argentine Society of Dermatology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
El/los autor/es tranfieren todos los derechos de autor del manuscrito arriba mencionado a Dermatología Argentina en el caso de que el trabajo sea publicado. El/los autor/es declaran que el artículo es original, que no infringe ningún derecho de propiedad intelectual u otros derechos de terceros, que no se encuentra bajo consideración de otra revista y que no ha sido previamente publicado.
Le solicitamos haga click aquí para imprimir, firmar y enviar por correo postal la transferencia de los derechos de autor
